Skip to main content
OpenTrials
Completed

NCT Number: NCT02512003

Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)

The FANTOM I pilot study is intended to assess safety of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient has evidence of myocardial ischemia or a positive functional study
  • Patient has a normal CK-MB
  • Target lesion has a visually estimated stenosis of ≥50% and <100%
  • Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.7mm and ≤ 3.3mm
  • Target lesion length must be ≤ 14mm

Exclusion criteria

  • Patient has experienced a myocardial infarction (CK-MB or Troponin > 5 X ULN) within 72 hours of the procedure
  • Patient has a left ventricular ejection fraction < 25%
  • Patient has unprotected lest main coronary disease with ≥50% stenosis
  • The target vessel is totally occluded (TIMI Flow 0 or 1)
  • Target lesion involves a bifurcation (a lesion with a side branch ≥ 2.0 mm in diameter containing a ≥ 50% stenosis).
  • Target lesion is located within a bypass graft
  • Target lesion has possible or definite thrombus

Treatment and study plan

Fantom Scaffold

Device

Primary outcomes

  1. Ischemia-driven Target Lesion Revascularization (TLR)

    Time frame: 4 months

    Percent of Patients with TLR at 4 months

Secondary outcomes

  1. Quantitative Coronary Angiography (QCA) derived parameters

    Time frame: 4 months

    Late Loss

  2. Quantitative Coronary Angiography (QCA) derived parameters

    Time frame: 4 months

    Restenosis Rate

  3. Quantitative Coronary Angiography (QCA) derived parameters

    Time frame: 4 months

    % Diameter Stenosis

  4. Quantitative Coronary Angiography (QCA) derived parameters

    Time frame: 4 months

    Minimum Lumen Diameter

  5. Quantitative Coronary Angiography (QCA) derived parameters

    Time frame: 4 months

    Neointimal Volume

  6. Intravascular Ultrasound (IVUS) derived parameters

    Time frame: 4 months

    Late Loss

  7. Intravascular Ultrasound (IVUS) derived parameters

    Time frame: 4 months

    Restenosis Rate

  8. Intravascular Ultrasound (IVUS) derived parameters

    Time frame: 4 months

    % Diameter Stenosis

  9. Intravascular Ultrasound (IVUS) derived parameters

    Time frame: 4 months

    Minimum Lumen Diameter

  10. Intravascular Ultrasound (IVUS) derived parameters

    Time frame: 4 months

    Neointimal Volume

  11. Major Adverse Cardiac Events

    Time frame: 12, 24, 36, 48 and 60 months

    Death, Q-Wave Myocardial Infarction, Non Q-Wave Myocardial Infarction (CK-MB > 5x normal), Target Vessel Revascularization

  12. Target Lesion Revascularization (TLR)

    Time frame: 12, 24, 36, 48 and 60 months

    Percentage of patients with TLR at each time point

  13. Target Vessel Revascularization

    Time frame: 12, 24, 36, 48 and 60 months

    Percentage of patients with TVR at each time point

  14. Target Vessel Failure (TVF)

    Time frame: 12, 24, 36, 48 and 60 months

    Percentage of patients with TVF at each time point

  15. Acute Technical Success

    Time frame: Day 0

    Percentage of patients with successful acute delivery and deployment of the device

  16. Procedural Success

    Time frame: 30 days

    Percentage of patients with angiographic success (final diameter stenosis <50% without occurrence of MACE)

  17. Optical Coherence Tomography (OCT) Imaging on a Subset of Patients

    Time frame: 4 months

    Qualitative measures in a subset of patients

Sponsors and collaborators

Lead sponsor

REVA Medical, Inc.

Industry

Registry information

Official study title

Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold

Acronym: FANTOM I

Important dates

Study start
2014
Primary completion
2015
Study completion
2020
First posted
Jul 30, 2015
Registry last updated
Mar 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.